Immunofoco
易慕峰生物
Immunofoco (易慕峰生物, also referred to as ImmuPharm) is a cell-therapy company developing what it calls a "dual engine" in solid tumors and in vivo CAR-T. In March 2026 it raised nearly RMB 200 million in a Pre-IPO round co-led by Gaorong Ventures and LYFE Capital, with continued follow-on from existing backer IN Capital; ZhenFund also appears among its angel investors . The company's iMAGIC platform has been validated in preclinical models targeting CD19, BCMA and CLDN18.2, with work presented at ASGCT and ASH meetings . It aims to become an immune-cell therapy drug developer focused on delivering long-term survival benefits for cancer patients globally .
AI-generated — may contain errors, please verify.
Coverage
Wanwu Capital | Z News
We invite you to revisit the July "highlight reel."
It's Spring Right Now | Z News
We're looking back at the "highlight moments" from the past two months, and we invite you to witness the growth of our portfolio companies and what's new at ZhenFund.
ImmuPharm Raises Nearly RMB 200 Million in Pre-IPO Round Co-Led by Gaorong Ventures, Building Dual Engine in Solid Tumors and In Vivo CAR-T
Bringing long-term survival benefits to cancer patients worldwide.
